NEWS legal form changed ByOncoscience 22. August 201717. July 2025 We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson. Ähnliche Beiträge
Allgemein | NEWS Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab. ByOncoscience 6. November 202017. July 2025
NEWS Oncoscience AG announces completion of patient enrollment in phase III trial of NIMOTUZUMAB, in first line treatment of children with inoperable brain cancer ByOncoscience 12. September 200717. July 2025
NEWS The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively ByOncoscience 26. October 200717. July 2025
NEWS Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the U.K. and Ireland ByOncoscience 3. October 201817. July 2025
NEWS Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. ByOncoscience 17. November 201717. July 2025
NEWS Innokeys Pte. Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG ByOncoscience 22. July 201517. July 2025
